DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

DENTSPLY SIRONA (NASDAQ:XRAY) had its price target boosted by equities research analysts at Wells Fargo & Company from $12.00 to $13.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price objective would indicate a potential downside of 9.88% from the stock’s current price.

Other equities research analysts have also issued reports about the company. Mizuho upped their price objective on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Tuesday, January 20th. Zacks Research cut DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a research report on Monday, November 10th. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $13.00 to $17.00 in a research note on Thursday, February 19th. Barclays started coverage on shares of DENTSPLY SIRONA in a report on Monday, December 8th. They issued an “underweight” rating and a $12.00 target price on the stock. Finally, JPMorgan Chase & Co. dropped their target price on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Three equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $14.69.

DENTSPLY SIRONA Stock Performance

XRAY stock traded up $1.72 during midday trading on Friday, hitting $14.43. The stock had a trading volume of 6,790,192 shares, compared to its average volume of 4,743,038. DENTSPLY SIRONA has a 52 week low of $9.85 and a 52 week high of $17.34. The company has a current ratio of 1.47, a quick ratio of 0.99 and a debt-to-equity ratio of 1.36. The stock has a 50-day simple moving average of $12.35 and a 200 day simple moving average of $12.47. The firm has a market capitalization of $2.88 billion, a price-to-earnings ratio of -3.26, a P/E/G ratio of 1.01 and a beta of 1.01.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 17.10% and a negative net margin of 24.34%.The business had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. During the same period in the previous year, the business posted $0.26 earnings per share. DENTSPLY SIRONA’s revenue was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts anticipate that DENTSPLY SIRONA will post 1.84 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Gregory T. Lucier sold 82,200 shares of DENTSPLY SIRONA stock in a transaction on Monday, December 8th. The stock was sold at an average price of $11.14, for a total value of $915,708.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.50% of the company’s stock.

Institutional Trading of DENTSPLY SIRONA

Hedge funds have recently modified their holdings of the company. Eurizon Capital SGR S.p.A. acquired a new stake in DENTSPLY SIRONA in the fourth quarter worth $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of DENTSPLY SIRONA in the 1st quarter valued at $26,000. Parkside Financial Bank & Trust raised its stake in DENTSPLY SIRONA by 620.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 1,477 shares during the period. Huntington National Bank lifted its holdings in DENTSPLY SIRONA by 292.9% during the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,077 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of DENTSPLY SIRONA by 337.9% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,122 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

Key DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Revenue beat and operational actions — Q4 revenue of $961M topped estimates and management announced a $120M annual restructuring to redirect spending into innovation, clinical & sales education, and connected-dentistry initiatives; investors view this as a credible turnaround lever. GlobeNewsWire release
• Positive Sentiment: Capital-allocation shift — Company eliminated its dividend to prioritize debt reduction and share repurchases, signaling management focus on balance-sheet repair and EPS accretion rather than cash returns. GlobeNewsWire release
• Neutral Sentiment: Analyst adjustment — Robert W. Baird raised its price target to $14 and kept a “neutral” rating, signaling tempered upside in analyst expectations despite the restructuring. TickerReport
• Negative Sentiment: EPS miss and impairment-driven loss — Reported GAAP loss (net loss $146M, -$0.74) driven by $144M goodwill/intangible impairments; adjusted EPS $0.27 missed consensus by $0.01. These hits and one-time charges weigh on near-term profitability metrics. GlobeNewsWire release
• Negative Sentiment: Softer FY26 guidance — Management set FY26 adjusted EPS $1.40–$1.50 and revenue $3.5–3.6B, both slightly below street expectations, leaving room for short-term disappointment if execution stalls. GlobeNewsWire release
• Negative Sentiment: Shareholder scrutiny — A law firm announced an investigation into potential fiduciary breaches, which could create governance/legal overhang. PR Newswire

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.